It is attributed with mucolytic properties, meaning that it acts as a decongestant to help loosen and literally digest mucus in the lungs. This is accomplished by dissolving certain proteins present in mucus by breaking the “disulfide bridge,” or the covalent bonds that link their thiol groups. Several clinical trials demonstrate this activity, making this substance a valuable treatment for chronic bronchitis, pneumonia, tuberculosis, emphysema, and chronic obstructive pulmonary disease (COPD).
Ambroxol is a mucolytic agent. Electron Microscope studies of nasal and bronchial mucosa suggest that increases lysosome activity and thus leads to increased secretion of enzymes capable of hydrolysing the mucopolysaccharide fibril structures of mucus. "Ambroxol has been reported to change the structure of Bronchial secretion and to increase the volume and reduce the viscocity of sputum". Ambroxol is metabolite of Bromhexine and has similar uses. It is administered as the hydrochloride and a daily dose of 30 to 120 mg has been given by mouth in 2 to 3 divided doses. Doses as high as 1 g. daily was well tolerated in lowering plasma uric acid concentration which goes to prove its safety. The recommended dose of Ambroxol Hydrocloride in children is 15 mg 2 to 3 times daily.